KCNQ channels as therapeutic targets
The present disclosure relates to methods and compositions for modulating the activity of KCNQ channels as a means for reducing the effects of aberrant KCNQ channel function associated with epilepsy, deafness and arrhythmias including but not limited to, Long-QT syndrome (“LQTS”), and atrial fibrillation. The present disclosure also relates to the discovery of certain regions of KCNQ channels that interact with various channel stimulating molecules such as, ATP, and PIP 2 , as well as KCNQ channel domains that effect voltage dependant channel activation. The disclosure is also directed to the use of small molecules to modulate KCNQ channel activity in a cell. Moreover, the present disclosure relates to the therapeutic effects of treating a subject with modulators of KCNQ channel activity.
1. A method of treating Long-QT syndrome (“LQTS”) in a subject in need thereof comprising administering an effective amount of an agent that modulates the activity of a KCNQ channel, wherein said agent is C28.
2. The method of claim 1 , wherein said KCNQ channel is an I Ks channel.
3. The method of claim 2 , wherein the agent modulates I Ks channel activity by altering voltage dependent activation of the I Ks channel.
4. The method of claim 1 , wherein said KCNQ channel is an M-channel.
5. The method of claim 4 , wherein the agent modulates M-channel activity by altering voltage dependent activation of the M-channel.
6. The method of claim 1 , wherein said KCNQ channel is KCNQ4 channel.
7. The method of claim 6 , wherein the agent modulates KCNQ4 channel activity by altering voltage dependent activation of KCNQ4 channels.
8. The method of claim 1 , wherein the agent modulates KCNQ channel activity by altering ATP binding to the KCNQ channel.
9. The method of claim 8 , wherein the agent modulates KCNQ channel activity by altering ATP binding to the KCNQ channel by interacting directly with a segment of the KCNQ1 protein comprising the amino acid sequence set forth in SEQ ID NO: 25.
10. The method of claim 1 , wherein the agent modulates KCNQ channel activity by altering PIP 2 binding to the KCNQ channel.
11. The method of claim 1 , wherein the agent increases KCNQ channel activity.
12. The method of claim 1 , wherein the agent reduces KCNQ channel activity.